hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06340308, orgStudyIdInfo id: PARAF 986117570, briefTitle: Clinical Study With Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol, acronym: PARAF, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-07, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of Pavia, class: OTHER, collaborators name: Foundation IRCCS San Matteo Hospital, descriptionModule briefSummary: To evaluate the effects of a nutraceutical containing Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol on lipid profile, conditionsModule conditions: Dyslipidemias, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol, interventions name: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol, outcomesModule primaryOutcomes measure: Variations of lipid profile, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Policlinico S. Matteo Foundation, status: RECRUITING, city: Pavia, zip: 27100, country: Italy, contacts name: Giuseppe Derosa, MD, PhD, role: CONTACT, email: giuseppe.derosa@unipv.it, contacts name: Pamela Maffioli, MD, role: CONTACT, email: p.maffioli@smatteo.pv.it, contacts name: Giuseppe Derosa, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Pamela Maffioli, MD, role: SUB_INVESTIGATOR, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06340269, orgStudyIdInfo id: PJ2308-0025, briefTitle: Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF, acronym: MexACLF, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Mexbrain, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from ACLF. The main questions it aims to answer are:* Is the device safe when used according to the instructions for use?* Does the device work as expected by removing the excess of free copper from the blood?Patients will receive 3 MEX-CD1 Slow Low volume CVVHD within 1 week., conditionsModule conditions: Acute on Chronic Liver Failure, conditions: Multiple Organ Failure, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, national, monocentric, single-arm, open label, feasibility pilot clinical trial., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: MEX-CD1 Dialysis, outcomesModule primaryOutcomes measure: SADE for Safety purpose, secondaryOutcomes measure: SAE for Safety purpose, secondaryOutcomes measure: Performance of MEX-CD1, secondaryOutcomes measure: Change in Acute on Chronic Liver Failure (ACLF) Grade, secondaryOutcomes measure: Change in CLIF-C ACLF score, secondaryOutcomes measure: Improvement in individual organ function, secondaryOutcomes measure: Development of secondary infection, secondaryOutcomes measure: Status of ICU, secondaryOutcomes measure: hospital discharge, secondaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital Croix Rousse, Service d'hépatologie et gastroentérologie, city: Lyon, state: Rhône-Alpes, zip: 69317, country: France, contacts name: Céline GUICHON, MD, role: CONTACT, phone: +33426109351, email: celine.guichon@chu-lyon.fr, contacts name: Céline Guichon, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.74848, lon: 4.84669, hasResults: False
protocolSection identificationModule nctId: NCT06340256, orgStudyIdInfo id: IRB0000871253, briefTitle: Continuous Spinal Anesthesia Versus Epidural Anesthesia in Geriatric, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-09-18, primaryCompletionDateStruct date: 2023-08-02, completionDateStruct date: 2023-08-15, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: 60 patients aged older than 60 years, American Society of Anesthesiologists (ASA) class II or III and scheduled for major hip surgery will be randomized, in to two groups anesthetized using continuous spinal anesthesia or using continuous epidural anesthesia., conditionsModule conditions: Epidural Catheter, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Continuous spinal anesthesia, interventions name: Continuous epidural anesthesia, outcomesModule primaryOutcomes measure: Hemodynamic changes, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Al-Azhar Faculty of Medicine, city: Assiut, country: Egypt, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06340243, orgStudyIdInfo id: HODGKIN, briefTitle: Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome, conditionsModule conditions: Pediatric Hodgkin Lymphoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: radiotherapy, outcomesModule primaryOutcomes measure: assess the outcome of pediatric patients with HL treated with risk- and response-adjusted therapy, eligibilityModule sex: ALL, minimumAge: 1 Month, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06340230, orgStudyIdInfo id: BC-NEO-IIT-SHR-A1811-SHR1316, briefTitle: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-02-28, completionDateStruct date: 2031-02-28, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Shengjing Hospital, class: OTHER, collaborators name: Jiangsu HengRui Medicine Co., Ltd., descriptionModule briefSummary: This is an open-label, phase II study evaluating the efficacy and safety of SHR-A1811 alone or in combination with Adebrelimab in Stage II-III ER Positive/HER2 Low Breast Cancer. Subjects will receive the neoadjuvant therapy of SHR-A1811 alone or in combination with Adebrelimab for six cycles, and then undergo surgery within 4 weeks after neoadjuvant therapy. Efficacy will be assessed every 2 cycles., conditionsModule conditions: ER Positive/HER2 Low Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 93, type: ESTIMATED, armsInterventionsModule interventions name: SHR-A1811 Injection + Adebrelimab Injection, interventions name: SHR-A1811 Injection + Adebrelimab Injection, interventions name: SHR-A1811 Injection, outcomesModule primaryOutcomes measure: Total pathological complete response (tpCR: ypT0-is/ypN0), secondaryOutcomes measure: Breast pathological complete response (bpCR：ypT0-is), secondaryOutcomes measure: Residual cancer burden (RCB), secondaryOutcomes measure: Best overall response rate (BORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Disease-free survival (DFS), secondaryOutcomes measure: Event-free survival (EFS), secondaryOutcomes measure: Health-related quality of life (HRQOL) (EORTC QLQ-C30), secondaryOutcomes measure: Health-related quality of life (HRQOL), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shengjing Hospital affiliated to China Medical University, city: Shenyang, state: Liaoning, zip: 110004, country: China, contacts name: Nan Niu, MD, role: CONTACT, phone: +8618940256668, email: niunannancy@163.com, contacts name: Caigang Liu, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.79222, lon: 123.43278, hasResults: False
protocolSection identificationModule nctId: NCT06340217, orgStudyIdInfo id: WMT-GDP-RCT, briefTitle: Washed Microbiota Transplantation for Diabetic Gastroparesis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2029-01, completionDateStruct date: 2029-07, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: The Second Hospital of Nanjing Medical University, class: OTHER, descriptionModule briefSummary: This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients., conditionsModule conditions: Diabetic Gastroparesis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 46, type: ESTIMATED, armsInterventionsModule interventions name: washed microbiota transplantation, interventions name: placebo, outcomesModule primaryOutcomes measure: The proportion of DGP with symptom relief after the procedure., secondaryOutcomes measure: The extent of change observed in GCSI of participants;, secondaryOutcomes measure: The extent of change observed in Gastroparesis Core Symptom Daily Diary (GCS-DD) of participants;, secondaryOutcomes measure: The extent of change observed in Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) of participants;, secondaryOutcomes measure: The extent of change observed in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QoL) of participants;, secondaryOutcomes measure: The extent of change observed in electrogastrogram (EGG) of participants;, secondaryOutcomes measure: The extent of change observed in electrogastrogram (EGG) of participants;, secondaryOutcomes measure: The extent of change observed in gastrointestinal ultrasound (GIUS) of participants;, secondaryOutcomes measure: The incidence rate of adverse events;, secondaryOutcomes measure: The changes in gut microbiota composition and metabolites before and after treatment., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, city: Nanjing, state: Jiangsu, zip: 210011, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06340204, orgStudyIdInfo id: PKUPH-EWS-03, briefTitle: Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2026-03-25, completionDateStruct date: 2026-12-25, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, collaborators name: Peking University Shougang Hospital, collaborators name: Shandong Cancer Hospital and Institute, descriptionModule briefSummary: The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma., conditionsModule conditions: Ewing Sarcoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: Irinotecan Hydrochloride Liposome Injection, outcomesModule primaryOutcomes measure: maximum tolerated dose (MTD), secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Progression Free Survival (PFS), eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 40 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Shandong Cancer Hospital and Institute, status: NOT_YET_RECRUITING, city: Jina, state: Shandong, zip: 250117, country: China, contacts name: Dongyuan Zhu, M.D., role: CONTACT, email: 405683898@qq.com, locations facility: Peking University Shougang Hospital, status: NOT_YET_RECRUITING, city: Beijing, zip: 100043, country: China, contacts name: Jin GU, M.D., role: CONTACT, email: jingu_1999@yahoo.com, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Peking University People's Hospital, status: RECRUITING, city: Beijin, zip: 100034, country: China, contacts name: Jie Xu, M.D., role: CONTACT, phone: +86 15901040835, email: xujie@pkuph.edu.cn, contacts name: Xiaodong Tang, M.D., role: PRINCIPAL_INVESTIGATOR, contacts name: Lu Xie, M.D., role: SUB_INVESTIGATOR, hasResults: False
protocolSection identificationModule nctId: NCT06340191, orgStudyIdInfo id: UJAPIlates1, briefTitle: Cueing and Pilates in Low Back Pain, acronym: PIlatesuja, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-02, primaryCompletionDateStruct date: 2024-02-20, completionDateStruct date: 2024-02-26, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of Jaén, class: OTHER, descriptionModule briefSummary: The intervention involved two groups participating in supervised Pilates sessions, twice a week for 8 weeks, featuring a mix of mat and props-based exercises. Group 1 received additional cueing training to enhance alignment, muscle engagement, and movement technique, while Group 2 underwent the same Pilates regimen without this cueing component., conditionsModule conditions: Low Back Pain, conditions: Pilates Exercise, conditions: Pilates, Core Stability, conditions: Mind-body Exercise, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 67, type: ACTUAL, armsInterventionsModule interventions name: Pilates with cueing, interventions name: Pilates without cueing, outcomesModule primaryOutcomes measure: Low back pain, primaryOutcomes measure: Pain report, secondaryOutcomes measure: Fear of movement, secondaryOutcomes measure: Perceived Stress Scale, secondaryOutcomes measure: Pain self-efficacy, secondaryOutcomes measure: Patient Impression of Change, secondaryOutcomes measure: Body Awareness, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Jaen, city: Jaen, zip: 23071, country: Spain, geoPoint lat: 37.76922, lon: -3.79028, hasResults: False
protocolSection identificationModule nctId: NCT06340178, orgStudyIdInfo id: 2024-00246, briefTitle: CT-guided Lung Biopsy Risk Optimization Method, acronym: BROM-I, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Insel Gruppe AG, University Hospital Bern, class: OTHER, descriptionModule briefSummary: The purpose of this randomized controlled study is to evaluate the extent to which injection of a small amount of fluid in the pleural cavity at the biopsy site may reduce the risk of pneumothoraces, in addition to patient positioning to allow biopsy in gravity-dependent areas of the lung., conditionsModule conditions: Pneumothorax, conditions: Biopsy, Needle, conditions: Risk Factors, conditions: Radiology, Interventional, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 198, type: ESTIMATED, armsInterventionsModule interventions name: Fluid application during ct-guided lung biopsy, outcomesModule primaryOutcomes measure: Number of patients with pneumothorax, secondaryOutcomes measure: Number of patients with bleeding, secondaryOutcomes measure: Number of patients with chest tube placement, secondaryOutcomes measure: Number of patients with air embolism, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 10, city: Bern, zip: 3010, country: Switzerland, geoPoint lat: 46.94809, lon: 7.44744, hasResults: False
protocolSection identificationModule nctId: NCT06340165, orgStudyIdInfo id: 2023-KS-151, briefTitle: A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-04, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: The First Hospital of Jilin University, class: OTHER, descriptionModule briefSummary: This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and different molecular subtypes of breast cancer. Evidence-based medicine evidence for clinicians. Although the clinical application of amlotinib in breast cancer treatment is a supra-indication drug, in view of its high safety and possible good efficacy for advanced breast cancer, some patients have been clinically adopted to try the treatment after communicating with their families. This study provides evidence for the further use of amlotinib in breast cancer treatment by analysing the efficacy and safety of amlotinib in real-world applications., conditionsModule conditions: Breast Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 153, type: ESTIMATED, armsInterventionsModule interventions name: Anlotinib, outcomesModule primaryOutcomes measure: PFS, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Jilin University, status: RECRUITING, city: Changchun, state: Jilin, zip: 130021, country: China, contacts name: xu sun, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.88, lon: 125.32278, hasResults: False
protocolSection identificationModule nctId: NCT06340152, orgStudyIdInfo id: 808385, secondaryIdInfos id: U01HG013189-01, type: NIH, link: https://reporter.nih.gov/quickSearch/U01HG013189-01, briefTitle: Multi-Omics for Maternal Health After Preeclampsia, acronym: MOM-Health, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-20, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2028-12, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of California, San Diego, class: OTHER, collaborators name: National Human Genome Research Institute (NHGRI), collaborators name: Vanderbilt University Medical Center, descriptionModule briefSummary: To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies., conditionsModule conditions: Pre-Eclampsia, conditions: Pregnancy Induced Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 1100, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Preeclampsia, primaryOutcomes measure: Gestational hypertension, primaryOutcomes measure: Postpartum hypertension, secondaryOutcomes measure: Postpartum cardiovascular disease, otherOutcomes measure: Other cardiovascular disease, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: University of California, San Diego, status: RECRUITING, city: San Diego, state: California, zip: 92037, country: United States, contacts name: Samantha La Belle, role: CONTACT, phone: 858-249-5985, email: slabelle@health.ucsd.edu, contacts name: Louise Laurent, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Marni Jacobs, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.71533, lon: -117.15726, hasResults: False